These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 12422914)
1. Screening for antimalarial toxicity: current concepts. Easterbrook M Can J Ophthalmol; 2002 Oct; 37(6):325-8, 331-4. PubMed ID: 12422914 [No Abstract] [Full Text] [Related]
2. Current concepts in monitoring patients on antimalarials. Easterbrook M Aust N Z J Ophthalmol; 1998 May; 26(2):101-3. PubMed ID: 9630287 [No Abstract] [Full Text] [Related]
3. Detection and prevention of maculopathy associated with antimalarial agents. Easterbrook M Int Ophthalmol Clin; 1999; 39(2):49-57. PubMed ID: 10343924 [TBL] [Abstract][Full Text] [Related]
4. What is new in recommendations on ophthalmological screening in patients treated with chloroquine and hydroxychloroquine? Update and literature review. Wiacek MP; Bobrowska-Snarska D; Lubiński W; Brzosko M; Modrzejewska M Niger J Clin Pract; 2017 Aug; 20(8):919-923. PubMed ID: 28891533 [TBL] [Abstract][Full Text] [Related]
5. Retinal toxicity induced by antimalarial drugs: literature review and case report. Garza-Leon M; Flores-Alvarado DE; Muñoz-Bravo JM Medwave; 2016 Jun; 16(5):e6471. PubMed ID: 27391903 [TBL] [Abstract][Full Text] [Related]
6. Is corneal deposition of antimalarial any indication of retinal toxicity? Easterbrook M Can J Ophthalmol; 1990 Aug; 25(5):249-51. PubMed ID: 2207871 [TBL] [Abstract][Full Text] [Related]
7. Ophthalmologic considerations in using antimalarials in the United States. Rynes RI Lupus; 1996 Jun; 5 Suppl 1():S73-4. PubMed ID: 8803917 [TBL] [Abstract][Full Text] [Related]
8. [Ophthalmologic prevention of chloroquine and hydroxychloroquine induced retinopathy]. Bui Quoc E; Ingster-Moati I; Rigolet MH; Chosidow O; Bodaghi B Ann Dermatol Venereol; 2005 Apr; 132(4):329-37. PubMed ID: 15886559 [TBL] [Abstract][Full Text] [Related]
9. Retinopathy and antimalarial drugs--the British experience. Spalton DJ Lupus; 1996 Jun; 5 Suppl 1():S70-2. PubMed ID: 8803916 [TBL] [Abstract][Full Text] [Related]
11. How frequently and how soon should we screen our patients for the presence of antimalarial retinopathy? Alarcón GS Arthritis Rheum; 2002 Feb; 46(2):561. PubMed ID: 11840465 [No Abstract] [Full Text] [Related]
12. Chloroquine-induced retinal toxicity. Whitelaw D; Jessop S S Afr Med J; 2005 Feb; 95(2):72. PubMed ID: 15751191 [No Abstract] [Full Text] [Related]
13. Hydroxychloroquine-induced retinopathy: a dermatologic perspective. Tripp JM; Maibach HI Am J Clin Dermatol; 2006; 7(3):171-5. PubMed ID: 16734504 [TBL] [Abstract][Full Text] [Related]
14. Early detection of macular changes with multifocal ERG in patients on antimalarial drug therapy. Nebbioso M; Grenga R; Karavitis P J Ocul Pharmacol Ther; 2009 Jun; 25(3):249-58. PubMed ID: 19348599 [TBL] [Abstract][Full Text] [Related]
15. Hydroxychloroquine: A Brief Review on Screening, Toxicity, and Progression. Modi YS; Singh RP; Fine HF Ophthalmic Surg Lasers Imaging Retina; 2016 Mar; 47(3):207-17. PubMed ID: 26985794 [No Abstract] [Full Text] [Related]
16. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Michaelides M; Stover NB; Francis PJ; Weleber RG Arch Ophthalmol; 2011 Jan; 129(1):30-9. PubMed ID: 21220626 [TBL] [Abstract][Full Text] [Related]